


Cite this: *RSC Adv.*, 2025, 15, 5703

Design, synthesis and biological activity of peptidyl β -nitrostyrenes as cysteine protease inhibitors against *Leishmania donovani*†

Sweta Sharma,^a Mirza A. Beg,^b Insha Latief,^a Jyoti Aboti,^a Samra Jamal,^c Pallavi Juneja,^d Supriya Tanwar,^d Kalicharan Sharma,^{id e} Sayeed ur Rehman,^{*d} Angamuthu Selvapandiyan^{*b} and Syed Shafi^{id *a}

Cysteine proteases are essential for the survival of *Leishmania* parasites that cause several clinical forms of leishmaniasis. Inhibiting cysteine protease can be a promising strategy against parasitic diseases because of their essential functions in the life cycles of these pathogens. The aim of the present study was to synthesize and evaluate peptidyl β -nitrostyrenes as antipromastigote inhibitors against *Leishmania donovani* promastigotes. A library of 12 peptidyl β -nitrostyrenes was synthesized and evaluated for anti-promastigote activity. Most of the compounds exhibited comparable activity to the standard, with IC_{50} values ranging from 1.468 to 16.81 μ M. Notably, compounds **14a**, **14e**, **14f**, and **14g** showed significant activity against both *L. donovani* promastigotes and intracellular amastigotes. Compounds **14e** and **14f** displayed superior anti-promastigote activity with IC_{50} values of 1.468 μ M and 1.551 μ M, respectively, compared to the standard (IC_{50} = 3.073 μ M). Moreover, compounds **14e** and **14f** demonstrated better inhibitory potential against intracellular amastigotes, with IC_{50} values of 1.28 μ M and 0.64 μ M, respectively, outperforming AmphoB (IC_{50} = 3.07 μ M). Additionally, compounds **14a** and **14g** showed negligible cytotoxicity to mammalian macrophages even at a concentration of 28 μ M. Given their high activity, favorable safety profiles, and cost-effective synthesis, this class of compounds holds promise for the development of anti-leishmanial drugs.

Received 9th September 2024
Accepted 15th December 2024

DOI: 10.1039/d4ra06510g

rsc.li/rsc-advances

1. Introduction

Leishmaniasis is a neglected tropical disease caused by parasites from the genus *Leishmania*. The WHO has identified it as one of 17 such diseases that pose a significant threat to mankind in tropical regions where over a billion people are directly exposed to tropical parasites.¹ Major pharmaceutical companies have largely overlooked such diseases in their drug discovery programs due to the lack of financial return.¹ The burden of Leishmaniasis is concentrated in a few countries, and

environmental factors like massive migrations, urbanization, deforestation, and new irrigation schemes, as well as individual risk factors like HIV, malnutrition, and genetics, contribute to its continued prevalence.^{2,3} Leishmaniasis can manifest in various ways, with the most common forms being cutaneous and visceral, ranging from asymptomatic to chronic disease. The type of Leishmaniasis a person gets depends on various factors relating to the patient and the parasite causing the disease.⁴

Cysteine proteases are important enzymes in parasitic organisms and are critical to their replication, virulence, and survival. They are particularly essential to *Trypanosoma* and *Leishmania* species, making them attractive targets for developing therapeutic agents against parasitic infections.⁵ Inhibiting cysteine proteases can be a promising strategy against parasitic diseases because of their essential functions in the life cycles of these pathogens. Researchers have been investigating this approach for years and have made significant strides in developing cysteine protease inhibitors.^{6,7}

Animal trials have shown the potential of these inhibitors in treating diseases caused by parasites like malaria, *Leishmania*, and *Trypanosoma cruzi*. *Leishmania* secretes several cysteine proteases, including cathepsin L-like proteases, cathepsin B-like proteases, and papain-like proteases, which are involved

^aDepartment of Chemistry, School of Chemical and Life Sciences, Jamia Hamdard, New Delhi, India. E-mail: syedshafi@jamiahamdard.ac.in

^bDepartment of Molecular Medicine, School of Interdisciplinary Sciences and Technology, Jamia Hamdard, New Delhi 110062, India. E-mail: selvapandiyan@jamiahamdard.ac.in

^cDepartment of Biotechnology, School of Chemical and Life Sciences, Jamia Hamdard, New Delhi, India

^dDepartment of Biochemistry, School of Chemical and Life Sciences, Jamia Hamdard, New Delhi, India. E-mail: Sayeed.rehman@jamiahamdard.ac.in

^eDepartment of Pharmaceutical Chemistry, ISF College of Pharmacy, Moga, Punjab, India

† Electronic supplementary information (ESI) available: Experimental procedure and characterization of new compounds (¹H and ¹³C NMR spectra). See DOI: <https://doi.org/10.1039/d4ra06510g>






Fig. 1 Cysteine Protease Inhibitors (CPIs) as chemotherapy for parasitic infections.

in nutrient acquisition, host cell invasion, and immune evasion.^{8–10} The mechanism of action of cysteine proteases involves the deprotonation of a nucleophilic cysteine thiol in the enzyme's active site. Michael acceptors, which interact with these thiol groups through a Michael-type addition (Fig. 1), can inhibit the protease's activity, making them potent covalent inhibitors. This property has been exploited in designing inhibitors for leishmaniasis.^{11,12}

The versatility and therapeutic potential of β -nitrostyrenes have been demonstrated across a range of applications, from antifungal agents to inhibitors of vital proteases like the SARS-CoV-2 3CL protease.^{7,13–15} Their effectiveness in disrupting the cellular processes of pathogens positions β -nitrostyrenes as valuable leads in the development of new antimicrobial agents.^{16,17} Syed Shafi and colleagues created a library of thirty β -nitrostyrenes and evaluated their efficacy against *L. donovani*, uncovering potent anti-leishmanial activity in both promastigote and amastigote forms. Notably, compound **1a**, featuring a methoxy group at the *para*-position and a methyl substituent at the β -position, demonstrated remarkable anti-leishmanial effects, with IC_{50} values of 40.50 ± 1.47 nM (promastigotes) and 26.43 ± 2.71 nM (amastigotes). Similarly, compound **1b**, distinguished by a hydroxy group at the *para*-position and an ethyl group at the β -position (Fig. 2), displayed significant activity, with IC_{50} values of 55.66 ± 2.84 nM (promastigotes) and 61.63 ± 8.02 nM (amastigotes).¹⁸ Ze-jun Jia *et al.* have reported β -nitrostyrenes as inhibitors of SARS-CoV-2 3CL protease, which is a key enzyme in the replication of the COVID-19 virus. The study identified seven β -nitrostyrene derivatives and found that 4-nitro- β -nitrostyrene, **2** showed the lowest IC_{50} values of 0.7297 μ M.¹⁹ These findings position these β -nitrostyrenes as promising candidates for further development into anti-leishmanial therapeutics.




Fig. 2 β -Nitrostyrenes as therapeutics.




Fig. 3 Peptidyl hybrids as anti-leishmanial agents.

Recent studies have further established the significance of peptidyl hybrids as promising cysteine protease inhibitors (Fig. 3). In the realm of anti-leishmanial research, Ahmed H. E. Hassan and his team have made significant contributions with the synthesis of chromone-peptidyl hybrids as potential anti-leishmanial hits against visceral leishmaniasis. Three hybrids demonstrated notable IC_{50} values against *L. donovani*, with values of 9.8, 10, and 12 μ M, respectively, rivalling that of erufosine ($IC_{50} = 9.8$ μ M). Importantly, preliminary cytotoxicity assessments revealed that hybrids **3a** and **3b** were non-cytotoxic up to 100 μ M, unlike erufosine, which exhibited a CC_{50} value of 19.4 μ M. Furthermore, Hassan's group also identified rosmarinic acid- β -amino- α -ketoamide hybrids, with two notable compounds, **3c** and **3d**, showing promising antileishmanial activity and negligible cytotoxicity, marking them as potential candidates for further development. Additionally, Mayara Castro de Morais and colleagues evaluated the antileishmanial potential of cinnamic acid derivatives against *L. infantum*. Compounds **3e** and **3f** stood out, showing strong anti-leishmanial activity with IC_{50} values of 33.71 μ M and 42.80 μ M, respectively, and high selectivity indices, indicating their potential as safer, more targeted treatments compared to traditional drugs like amphotericin B. Compound S9 (**3g**) displayed excellent leishmanicidal activity²⁰ against *L. major* promastigotes ($IC_{50} = 37.4$ μ M) and amastigotes ($IC_{50} = 2.3$ μ M). Compounds CPB2.8DCTE (**3h**) exhibited potential anti-leishmanial activity against *Leishmania Mexicana* cysteine protease ($IC_{50} = 3.7$ μ M).²¹ The exploration of peptidyl β -nitrostyrenes and their biological evaluation as cysteine protease inhibitors represents a cutting-edge approach in the ongoing quest for effective treatments against parasitic diseases.

The rational approach for the designing the new molecules is shown in Fig. 4. The design of the final molecules was inspired by previous studies demonstrating the anti-leishmanial potential of β -nitrostyrenes. Syed Shafi and colleagues synthesized






Fig. 4 Rationale design for target molecules.

a library of β -nitrostyrenes and identified 4-hydroxy β -nitrostyrene with significant activity against *Leishmania donovani*.^{7,18} Building on these findings, we aimed to enhance their therapeutic potential by incorporating the peptidyl motif, which is known to increase selectivity for cysteine proteases. Previous reports have shown that Michael acceptor-type inhibitors, such as peptidyl nitroalkenes, effectively inhibit cysteine proteases like cruzipain and rhodesain with nanomolar potency.²² Additionally, compounds like K11777 and other α,β -unsaturated esters have been successfully used to target viral and parasitic proteases, further validating the use of Michael acceptors for enzyme inhibition.^{23–27}


In the present study, we applied the hybrid conjugation of β -nitro styrene with different amino acids with diverse chemical structures allowing detailed characterization of the residue preference of the binding pocket within the substrate-binding site of the protease (Fig. 4).

2. Results and discussion


2.1 Chemistry

The designed peptidyl β -nitrostyrenes were prepared by employing a multistep synthetic strategy. The retrosynthetic analysis of the target molecule results in two important building blocks *viz.* fragment A, non-peptidyl β -nitrostyrene attached to a carboxylic acid linker and fragment B, a dipeptidyl moiety (Scheme 1).


Fragment A (**10**) was prepared by reacting (*E*)-4-(2-nitrobut-1-en-1-yl)phenol (**9**) with bromoacetic acid in the presence of K_2CO_3 . (*E*)-4-(2-Nitrobut-1-en-1-yl)phenol (**9**) was obtained by Henry reaction by reacting *p*-hydroxybenzaldehyde (**8**) with nitropropane using ammonium acetate as a base (Scheme 2).




Scheme 1 Retrosynthetic analysis of target molecule.



Scheme 2 Synthetic protocol for acid (fragment A).



Scheme 3 Synthetic protocol for peptides (fragment B).




Scheme 4 Synthetic protocol for peptides (fragment B).

Boc-protected fragment B was synthesised by coupling various Boc-protected amino acids (**12a–k**) with morpholine/thiomorpholine/amino acid methyl esters under EDC coupling conditions (Scheme 3). Finally, deprotection of the Boc group resulted in fragment B (**13a–k**) with the free $-NH_2$ group which was directly used for further coupling reaction, without any purification.

Both the fragments were finally combined by employing EDC coupling to obtain the peptidyl β -nitrostyrenes (**14a–k**) as shown below in Scheme 4.

By employing the above multistep synthetic strategy, a library of eleven peptidyl β -nitrostyrenes were prepared, as

Fig. 5 Synthesized Peptidyl β -nitrostyrenes.

depicted in Fig. 5. The formation of all the synthesized compounds was confirmed by various analytical techniques, including ^1H NMR, ^{13}C NMR, Mass and IR.

The formation of compound **9** was confirmed by the appearance of a characteristic vinyl proton signal at δ 8.0 ppm, ethyl signals at δ 2.88 and 1.28 ppm along with the aromatic signals in ^1H NMR. The ^1H NMR values for compound **10** are in correlation with the literature values.¹⁸ The appearance of two singlets, one corresponding to $-\text{COOH}$ proton and the other for $-\text{CH}_2$ at δ 13.2 and 4.7 ppm, respectively along with aromatic/aliphatic protons in the ^1H NMR confirmed the formation of compound, **10**. The formation of peptide fragments **12a–g** was confirmed by the appearance of two multiplets between δ 3.73–3.56 and 2.87–2.70 ppm. Further, the formation of dipeptide fragments **12h–k** was confirmed by the peaks in the aliphatic region and the $-\text{NH}$ peak in ^1H NMR spectrum. Finally, the formation of peptidyl β -nitrostyrenes (**14a–k**) through EDC coupling of **10** and **13(a–k)** was confirmed by the missing peak for $-\text{COOH}$ proton and the appearance of a new amide peak in the range of δ 3.00–4.00 ppm along with signals belonging to both fragments. The presence of signals at δ 169.51–115.45 ppm and 67.27–12.52 ppm in the ^{13}C NMR further confirms the formation of a new amide bond between both fragments. Finally, the formation of all the peptidyl β -nitrostyrenes, **14a–k** was confirmed by mass spectroscopy.

2.2 Pharmacology

2.2.1 Primary screening against *L. donovani* promastigotes. The *in vitro* activities were evaluated for all the peptidyl and dipeptidyl β -nitrostyrene derivatives against both *L. donovani* promastigotes and amastigotes. All the derivatives were first screened against promastigote forms to determine their percentage inhibition at 100 μM concentration. It was observed that nine of the Peptidyl β -nitrostyrenes (**14a–i**) exhibited a high inhibitory activity at 100 μM concentrations which was better than Amphotericin B (Table 1). The range of % inhibition was (80–85), respectively. Compounds showing 80% and above growth inhibition were screened further to obtain their IC_{50} values. These IC_{50} values were obtained using a dose-response curve (Fig. 6 and 9).

Table 1 Primary screening against *L. Donovani* promastigotes

S no.	Test samples	% inhibition (48 h)
1	14a	84.8
2	14b	83.7
3	14c	82.4
4	14d	80.8
5	14e	80.4
6	14f	77.9
7	14g	78.1
8	14h	82.2
9	14i	84.5
10	14j	65.5
11	14k	54.8
12	AmphoB	78.5




Fig. 6 Primary screening graph.

2.2.2 IC_{50} calculation against *L. donovani* promastigotes.

The IC_{50} values of the derivatives were obtained using a serial dilution method. Most of the compounds showed significant anti-promastigote activity. All compounds demonstrated comparable anti-promastigote activity as compared to standard with IC_{50} values ranging between 1.468–16.81 μM as shown below in Table 2 and Fig. 7.

Table 2 IC_{50} values against *L. donovani* promastigotes

Molecules	IC_{50} (μM)
● 14a	11.87
■ 14b	16.81
▲ 14c	7.236
▼ 14d	7.563
◆ 14e	1.468
● 14f	1.551
■ 14g	14.42
▲ 14h	10.01
▼ 14i	5.298
◆ AmphoB	3.073




Fig. 7 IC_{50} values against *L. donovani* promastigotes.



Table 3 Cytotoxicity values for THP-1 human monocytic cells

	Log CC ₅₀	CC ₅₀		Log CC ₅₀	CC ₅₀
14a	1.458	28.68	14f	0.4741	2.979
14b	0.7734	5.934	14g	1.670	46.79
14c	0.5684	3.701	14h	1.109	12.86
14d	0.5025	3.180	14i	0.7120	5.153
14e	0.3743	2.367	STD	1.029	10.69

Compounds **14e** and **14f** demonstrated better anti-promastigote activity with IC₅₀ values of 1.468 μ M and 1.551 μ M, respectively, compared to standard (IC₅₀ = 3.073 μ M).

2.2.3 Cytotoxicity assay. *In vitro* cytotoxicity assay was performed with THP-1 human monocytic cells to investigate the cytotoxicity of nine derivatives with greater than 80% inhibition at 100 μ M concentrations along with amphotericin B, at varying concentrations. The toxicity assay illustrated that compounds **14a**, **14g**, and **14h** with CC₅₀ are safer than amphotericin B, as shown in Table 3 below.

Based on determined IC₅₀ values against *L. donovani* promastigotes and cytotoxicity studies (Fig. 8), it might be stated that derivatives **14a**, **14e**, **14f** and, **14g** could act as non-toxic and potent antileishmanial hit compounds for further research.

2.2.4 In vitro antileishmanial activity against intracellular amastigotes. Compounds showing good anti-promastigote activity and lower cytotoxicity, **14a**, **14e**, **14f**, and **14g** were further evaluated for antileishmanial potential in intracellular *L. donovani* amastigotes in infected macrophages. The percentage reduction in intracellular amastigotes was calculated by counting the macrophages (see Fig. 9) and are tabulated in Table 4. Additionally, the number of amastigotes for

Table 5 Calculation of selectivity index of **14a**, **14e**, **14f**, **14g** and amphotericin B

Molecules	IC ₅₀ (μ M)	CC ₅₀ (μ M)	SI
14a	8.07	28.68	3.55
14e	1.28	2.367	1.85
14f	0.64	2.979	4.65
14g	6.37	46.79	7.34
AmphoB	3.07	10.69	3.48

every 100 macrophages and the IC₅₀ values of each drug were calculated.

The intracellular amastigotes of *L. donovani* were inhibited by all four compounds, **14a**, **14e**, **14f** and **14g**. The inhibitory potential of compounds **14e** and **14f** with IC₅₀ values of 1.28 μ M and 0.64 μ M was better than AmphoB with IC₅₀ values of 3.07 μ M.

The selectivity data in Table 5 demonstrates that **14a** (SI 3.55), **14f** (SI 4.65), and **14g** (SI 7.34), were equally or more selective for *L. donovani* amastigotes than the host macrophages as compared to amphotericin B (SI 3.48).

2.2.5 Cellular morphological alteration in *L. donovani*. The cellular morphological changes in Leishmania parasites were revealed through microscopic evaluation of promastigotes treated with **14a**, **14e**, **14f** and **14g**. Promastigotes were exposed to the compounds and the standard for 48 hours. Changes were examined using a contrast microscope with 40 \times objective lens. The promastigotes displayed notable morphological alterations in the parasites, such as cell shrinkage, flagella loss, and




Fig. 8 Cytotoxicity graph against THP-1 human monocytic cells.

Table 4 Percentage reduction in intracellular amastigotes

SAMPLE	Percentage Reductions (%)			
	3.125 μ M	6.25 μ M	12.5 μ M	IC ₅₀ (μ M)
14a	37.2	44.1	57.5	8.07
14e	65.4	75.1	88.5	1.28
14f	63.2	73.4	90.3	0.64
14g	36.7	46.8	63.2	6.37
AmphoB	52.3	63.2	85.5	3.07




Fig. 9 Activity against intracellular amastigote.






Fig. 10 Analysis of cellular morphology effects of treated promastigotes with compounds. Exponential-phase promastigotes (2×10^6 cells per mL) were incubated with compounds analyzed by light microscopy (200 magnification), as described in Methods.

cytoplasmic condensation, leading to the complete circularization of promastigotes along with a substantially decreased size as compared to the untreated control. These changes in morphology suggest that the cells experienced apoptosis (Fig. 10), and were consistently observed in the treated promastigotes at both zero and 48 hours. Microscopic assessment of promastigotes treated with compound **14g** discloses the cellular morphological changes in *Leishmania* parasites. Briefly, promastigotes (2×10^6 cells per mL) were incubated in the absence or presence of compound **14g** and miltefosine for 48 h at the concentration of $1 \mu\text{M}$ and observed under a $40\times$ objective lens of contrast microscope. Microscopic observations revealed significant morphological changes in parasites, including cell shrinkage, loss of flagella, and cytoplasmic condensation, resulting in complete circularization of the promastigotes and substantial reduction in size compared to the untreated control. These changes are typical of programmed cell death and were also observed in treated parasites at zero and after 48 hours (Fig. 10).

2.2.6 Cysteine protease inhibition assay. Inhibition of cysteine protease (papain) was recorded with an increasing concentration of inhibitor (0–32 μM) using Bz-Arg-AMC hydrochloride as fluorogenic peptide substrate. The activity of papain was recorded for 120 min. As seen in Fig. 11, a decrease in the activity of papain with increasing concentration of inhibitor was observed. Insignificant activity of papain was recorded in the




Fig. 11 The activity of papain was studied in the absence and presence of an increasing inhibitor concentration. Different concentration of inhibitor is shown by different colors, with dark blue color depicting the activity in the absence of an inhibitor. The excitation wavelength was set at 348 nm and emission was recorded at 440 nm.

presence of the inhibitor at 32 μM concentration. From the data obtained above, % residual activity was calculated and plotted against the $\log[\text{inhibitor}]$ to calculate the IC_{50} value of the inhibitor. Using the equation of the straight line, IC_{50} for the inhibitor was found and presented in Table 6.



Table 6 IC₅₀ values against cysteine protease

Molecules	14a	14e	14f	14g
IC ₅₀ (μM)	9.63 ± 0.28	4.44 ± 0.59	7.30 ± 0.39	11.74 ± 0.48

2.2.7 In silico docking studies. *In silico* docking studies of the most active compounds **14a**, **14e**, **14f** and **14g** were conducted against *Leishmania mexicana* CPB in complex with an aza-nitrile inhibitor using Schrödinger software with PDB ID 6P4E. Docking scores for compounds **14a–i** are presented in Table 7.

Among all the docked compounds **14e**, **14f**, **14h**, **14j** and **14k** exhibited good docking scores against the targets (cysteine protease). All docked compounds possess in similar catalytic domain of cysteine protease (Fig. 12 and 13). In the *Leishmania mexicana* CPB structure (PDB ID 6P4E), both non-covalent hydrophilic and hydrophobic interactions were observed between these compounds and the protein. The compounds demonstrate pi-interactions with TRP 186 and form hydrogen bonds with LEU 162 and GLY 67. Furthermore, they exhibit hydrophobic interactions with LEU 68, MET 69, TRP 27, ALA 140, LEU 162, and TYR 210 amino acid residues. Additionally, they display some polar interactions with SER 65 in chain A, as shown in the 2D & 3D poses in Fig. 12.

Similarly, the standard exhibited hydrogen bonding with ASN163 amino acid residues in catalytic domain of cysteine protease and all our potent compounds possess similar binding pattern as per standard ligand. It also demonstrated hydrophobic interaction with TRP 27, MET 60, LEU 68, MET 69, ALA 140, LEU 162, TRP 186, and TYR 210 amino acids. Additionally, it displayed some polar interactions with GLN 20, SER 25, SER 65, GLN 71, ASN 163, and HIE 164 in chain A, and the 2D & 3D poses are given in Fig. 13. Further, we have superimposed all our potent compounds with standard ligand and found similar binding pattern against catalytic domain of cysteine protease. We have done the distance measurement from CYS26 catalytic site (Fig. 12H) and found that all residues were present within range. After that also compare the known inhibitor E64 with compound **14e** (Fig. 12I) and found similar catalytic domain.

2.2.8 Structure activity relationship (SAR). Based on the anti-leishmanial properties of the synthesized peptidyl β-nitrostyrenes; a clear SAR can be drawn as shown in Fig. 14. As illustrated in Fig. 14, there is a clear correlation between the

biological activity and the structural modifications at the peptidyl side chain, which appears to be largely favourable across nearly all compounds. The peptide fragment connected to the β-nitrostyrene core is vital for determining both binding affinity and efficacy. Notably, the peptidyl conjugates with heterocyclic moiety (**14a–14g**) demonstrated better efficacy when compared to the dipeptidyl ester conjugates (**14h–14k**). Among the peptidyl conjugates (**14a–14g**), compounds derived from phenyl alanine (**14a**), tryptophan (**14e**), and phenylglycine (**14g**) demonstrated promising antileishmanial activity when compared to the compounds derived from proline (**14c** and **14d**). Further, heterocyclic moiety was also found have greater influence on biological activity. Peptidyl conjugates derived from morpholine (**14a**, **14e** and **14g**) were found to demonstrate better activity when compared to the peptidyl conjugates derived from thiomorpholine.

These varying peptide linkers significantly affect biological activity based on factors like steric hindrance and chain flexibility. For instance, the presence of bulky or flexible linkers, as observed in **14e** and **14h**, alters the binding geometry, indicating that a more rigid structure could enhance interactions with the target protease's active site.

These modifications collectively emphasize the importance of specific peptide groups in optimizing the biological activity of these peptidyl β-nitrostyrenes. The MD simulations demonstrated that **14e**, featuring a combination of tryptophan and morpholine, exhibited remarkable stability, as evidenced by low root mean square fluctuations and consistent hydrogen bond interactions with the protein. This confirms its structural integrity and compatibility within the binding pocket under simulated physiological conditions.

2.2.9 ADMET analysis. The ADME characteristics of the synthesized compounds were evaluated using QikProp. Table 8 displays the results of the QikProp assessment for compounds **14a**, **14e**, **14f**, and **14g**. It was found that all compounds meet the acceptable ranges for ADME parameters.

2.2.10 Molecular dynamic simulation. Based on the docking results, molecular dynamic simulation studies were performed for compatibility, stability, conformational strength, and dynamic behaviour of protein–ligand complexes at the scale of atom. The top Glide XP docked compound, having significant non-bonded interactions and binding affinity between the protein and ligand complex, was subjected to MD simulation for a duration of 100 ns using GROMACS 2024.4. The results of the MD simulation are represented as root means square deviation (RMSD), root mean square fluctuation (RMSF), radius of gyration, hydrogen bonds, and solvent-accessible surface area (SASA) of protein and ligand complexes.

2.2.11 Root mean square deviation. In this current study, we performed 100 ns of molecular dynamics simulations on the target protein *Leishmania mexicana* cysteine protease B (LmCPB) system (PDB ID: 6P4E) in a complex with the top-scoring hit compound. The RMSD value for the protein–ligand complexes denotes the high of the protein–ligand complexes system that provides critical insights into the structural dynamics and stability of the system. In the case of MD simulation against LmCPB, the **14e**–LmCPB (red trajectory) complex slightly

Table 7 Docking scores of all synthesised compounds (**3a–s**) in the catalytic binding pocket of cysteine proteases (PDB ID: 6P4E)

Code	Docking score [kcal mol ^{−1}]	Code	Docking score [kcal mol ^{−1}]
14a	−4.195	14g	−4.620
14b	−4.463	14h	−6.140
14c	−5.300	14i	−5.108
14d	−4.452	14j	−5.979
14e	−5.480	14k	−6.105
14f	−5.515	Standard	−6.007






Fig. 12 (A) and (B) The docking pose of molecule **14e** is shown, in PDB ID 6P4E in 2D, and 3D, where it binds with LEU 162 and GLY 67 amino acid residues *via* hydrogen-bonding as represented by pink line; protein is displayed in ribbon representation (C) and (D) docking pose of **14f** is shown, in PDB ID 6P4E in a 2D and 3D structure, where it binds with GLY 67 amino acid residue *via* hydrogen bonding as represented by the pink line. (E) and (F) docking pose of **14h** is shown, in PDB ID 6P4E in a 2D and 3D structure, where it binds with GLY 67 amino acid residue *via* hydrogen bonding as represented by a pink line (G) The superimposable images of ligand **14h** and standard with the catalytic site (H) distance measurement from CYS26 catalytic site (I) superimposition of **14e** with E64.






Fig. 13 2d and 3D Binding interaction of standard ligand (dipeptidyl aza-nitrile) against cysteine protease (PDBID: 6P4E), where it binds with ASN 163 amino acid residue via hydrogen bonding as represented by a pink line. Protein is displayed in ribbon representation.

fluctuates, ranging from 0.1–0.3 nm, on the other hand, standard-LmCPB (black trajectory complexes were static and dynamic (0.1–0.2 nm) over the 100 ns simulation period, which provides further insight into the ligand's binding dynamics, as depicted in Fig. 15. Over the 100 ns simulation, compound **14e** slightly deviated in initial time from the binding pocket of the




Fig. 14 SAR for the synthesized compounds.

Table 8 *In silico* ADME prediction of synthesized compounds (**14a**, **14e**, **14f**, and **14g**) using Qikprop tool of Maestro

Code	14a	14e	14f	14g	STD
PSA ^a	117.272	133.044	110.681	114.779	107.84
QP log <i>P</i> o/w ^b	2.27	2.759	3.38	2.083	4.81
QP log <i>S</i> ^c	−2.386	−4.657	−5.365	−1.766	−6.57
Rule of five ^d	0	0	0	0	1
Donor HB ^f	0.25	1.25	0.25	0.25	1.25
Acceptor HB ^g	9.2	9.2	8	9.2	9.45
% HOA ^e	85.924	78.384	89.464	74.957	89.169

^a van der Waals surface area of polar nitrogen and oxygen atoms (range 7–200). ^b Predicted octanol/water partition coefficient (<5). ^c Predicted aqueous solubility, log *S*. *S* in mol dm³ is the concentration of the solute in a saturated solution that is in equilibrium with the crystalline solid (range −6.5 to 0.5). ^d Lipinski's violations (≤1). ^e % human oral absorption >80% is high, <25% is low. ^f Donor HB (0–6). ^g Acceptor HB (2–20).




Fig. 15 MD Simulation LmCPB–ligand complexes root mean square deviation (RMSD) for protein–ligand.

LmCPB protein. At the same time, the standard compound showed no deviation from the binding pocket of LmCPB protein systems as represented in Fig. 15. These deviations indicate the ligand's interaction stability within the enzyme's binding pocket throughout the simulation.

2.2.12 Root means square fluctuation. RMSF is a numerical measurement of individual residue flexibility or how much a particular amino acid residue moves (fluctuates) during an MD simulation. RMSF analysis shows a higher fluctuation for standard-LmCPB (black lines) than **14e**-LmCPB (red lines) shows the lowest fluctuations over the whole time which ranges from 0–0.55 nm, presented in Fig. 16. The residues indicating the highest fluctuation in the RMSF may be responsible for causing the deviation in the RMSD. This analysis analyzed RMSF for the protein structure complexed with ligands that provided insights into each atom's mean displacement throughout the 100 ns simulation period (Fig. 16).

2.2.13 Radius of gyration. The radius of gyration analysis is one of the important calculations for assessing the structural dynamic behaviour of protein, as it reflects changes in the






Fig. 16 MD Simulation LmCPB–ligand complexes root mean square fluctuation (RMSF) for protein.

compactness of the protein–ligand complexes throughout the 100 ns simulation. An initial approach to evaluating the stability of the protein is to compute the radius of gyration, a measure of the compactness of the protein structure. When analysing the gyration radius for the whole protein it is evident that the total gyration radius (R_g) does not change significantly over time, implying that the protein is not undergoing major structural changes (Fig. 17).

The radius of gyration for the protein–ligand complexes with **14e** and standard were analyzed. The average radius of gyration values was found to be 1.66 ± 0.03 nm for all protein–ligand complexes and can be represented as the arrangement of atoms around the axis and found to be quite stable throughout the 100 ns MD simulation run, depicted in Fig. 17.

2.2.14 Hydrogen bonds. Hydrogen Bonds calculation that the ligand molecules (**14e** and standard) formed with the target protein as depicted in Fig. 18. The stability and dynamic of the




Fig. 17 MD Simulation LmCPB–ligand complexes radius of gyration (R_g) for protein.




Fig. 18 MD Simulation LmCPB–ligand complexes: total number of hydrogen bonds for ligand.

intermolecular hydrogen bonds network between the ligand–protein complexes were analyzed and calculated throughout the 100 ns MD simulation run. The ligand–protein interactions were analyzed to compare the five ligands (Fig. 18) that represent the number of H-bond contacts between the ligands and the protein. It was evident from the plot that we were able to make for compound **14e** and standard 1–5 h-bond contacts with target protein LmCPB (Fig. 18).

2.2.15 Solvent accessible surface area. To analyze the structural compactness and solvent accessibility of all




Fig. 19 MD Simulation LmCPB–ligand complexes: SASA for protein–ligand.



complexes (**14e**–LmCPB and standard–LmCPB) we observe the solvent-accessible surface area (SASA). SASA analysis of protein–ligand complexes during MD simulations showed stable solvent exposure, indicating consistent folding and binding of ligand molecules into the active site of the target protein. It is defined as the surface characterized around a protein by a hypothetical centre of a solvent sphere with the van der Waals contact surface of the molecule. 41e–LmCPB complex depicts the highest value (around 118 nm²) of SASA as compared to standard–LmCPB complex (below 110 nm²) as depicted in Fig. 19. The complexes maintained structural integrity, confirming their stability under simulated physiological conditions (Fig. 19).

3 Conclusion

A library of 12 peptidyl β -nitrostyrenes was synthesized and tested for their efficacy against *L. donovani* promastigotes and amastigotes. Most of the compounds demonstrated comparable anti-promastigote activity to the standard with IC₅₀ values ranging between 1.468–16.81 μ M. Compounds **14a**, **14e**, **14f**, and **14g** exhibited significant activity against both *L. donovani* promastigotes and intracellular amastigotes. Compounds **14e** and **14f** demonstrated better anti-promastigote activity with IC₅₀ values of 1.468 μ M and 1.551 μ M respectively as compared to standard (IC₅₀ = 3.073 μ M). The inhibitory potential of **14e** and **14f** against intracellular amastigotes with IC₅₀ values of 1.28 μ M and 0.64 μ M was better than **AmphoB** with IC₅₀ value of 3.07 μ M. Additionally, insignificant cytotoxicity was seen for compounds **14a** and **14g** against mammalian macrophages even at a concentration of 28 μ M. Given their high activity, safety profiles, and the fact that they can be synthesized cost-effectively, this class of compounds could be potentially valuable for the development of anti-leishmanial drugs.

The use of peptidyl β -nitrostyrenes as inhibitors of cysteine proteases to treat *Leishmania donovani* represents a new approach compared to current anti-leishmanial therapies like miltefosine and amphotericin B, which target different biological processes. Miltefosine, the first oral drug for leishmaniasis, disrupts cell membrane integrity by affecting lipid metabolism, leading to a type of cell death in the parasite like apoptosis.^{28,29} While effective, its use is becoming limited due to emerging resistance.²⁹ On the other hand, amphotericin B, which binds to ergosterol in the parasite's membrane, causes cell lysis but has significant nephrotoxicity, making it less practical for widespread use, especially in resource-limited settings.^{29,30} In contrast, peptidyl β -nitrostyrenes act selectively by inhibiting cysteine proteases that are crucial for the parasite's survival, particularly in intracellular amastigotes. Compounds such as **14e** and **14f** in this study showed promising efficacy, with IC₅₀ values of 1.28 μ M and 0.64 μ M against intracellular amastigotes. Additionally, these compounds displayed low toxicity to mammalian macrophages, suggesting a favourable safety profile compared to miltefosine and amphotericin B. Although further optimization is necessary, the selective mechanism and initial efficacy of peptidyl β -nitrostyrenes make them promising candidates for future anti-leishmanial drug development.

4 Materials and methods

4.1 General

All reagents and chemicals used in this research were obtained from GLR, Sigma Aldrich, and Merck (India), and were of AR (analytical reagent) grade quality. The 0.25 mm silica gel 60–120 TLC plates were used to monitor the reactions. UV cabinet was used to visualize spots on the TLC to monitor the reactions. Bruker NMR spectrometer was used for ¹H and ¹³C NMR spectral analysis at 400 MHz and 100 MHz. The spectra were analyzed using Mestrenova software. The HRMS and ESI-MS were obtained on ESI-MS using an Agilent mass spectrometer. The IR spectra were obtained on a Bruker ALPHA FT-IR spectrometer. The Buchi Labortechnik AG 9230 automated melting point apparatus was used for determining the melting points of the derivatives. The identities of the compounds prepared in this study were confirmed through spectral analysis. The compounds were purified through column chromatography using 60–120 and 230–400 mesh sizes of silica gel and recrystallized in ethanol. Additional chemicals used in the *in vitro* assay including 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) were from BPS Biosciences.

4.2 Chemistry

4.2.1 Typical procedure synthesis of (E)-4-(2-nitrobut-1-en-1-yl)phenol (10). A solution of 4-hydroxybenzaldehyde (1.0 g, 8.20 mmol), 30 eq. of 1-nitropropane (22.0 mL, 250 mmol), and a catalytic amount of sodium acetate was taken in a round-bottom flask and refluxed for 12 hours. After completion of the reaction as confirmed by TLC, the reaction mixture was gradually cooled to ambient temperature, and the volume was reduced using a rotavapor. The reduced reaction mixture was quenched with excess water (30 mL) and extracted with ethyl acetate (3 \times 20 mL). The combined organic layers were dried using anhydrous sodium sulfate, filtered, and evaporated to yield the crude product. This crude product was subsequently recrystallised to afford the pure product (1.50 g, 98% yield); ¹H NMR (400 MHz, DMSO-d₆) δ (ppm): 8.00 (s, 1H), 7.37 (t, *J* = 8.0 Hz, 2H), 6.91 (t, *J* = 8.0 Hz, 2H), 5.37 (s, 1H), 2.88 (q, *J* = 8.0 Hz, 2H), 1.28 (t, *J* = 8.0 Hz, 3H); HRMS (Q-TOF, ESI) calcd for C₉H₉N₃O [M + H]⁺ 194.0, found 194.0.

4.2.2 Typical procedure for synthesis of (E)-2-(4-(2-nitrobut-1-en-1-yl)phenoxy)acetic acid (11). To the dry acetone (10 mL) solution of (E)-4-(2-Nitrobut-1-en-1-yl)phenol, 10 (1.0 g, 5.20 mmol), 1.2 eq. of bromoacetic acid (0.86 g, 6.24 mmol) was added. The reaction was then charged with activated K₂CO₃ (3.60 g, 5 equiv.) in portions. The reaction was refluxed for 11–12 hours. After completion of the reaction as confirmed by TLC, the reaction mixture was gradually cooled to ambient temperature, resulting in the formation of a precipitate. The precipitate obtained was filtered, dissolved in water, and neutralized with 2 M HCl until reaching a pH of 7. The precipitate obtained in the neutralized mixture was filtered off, washed with an excess of water, and subsequently dried under vacuum to obtain the pure off-white solid product (0.12 g, 90% yield); ¹H NMR (400



MHz, DMSO-d₆) δ (ppm): 13.2 (s, 1H), 8.04 (s, 1H), 7.56 (d, J = 8.0 Hz, 2H), 7.05 (d, J = 12.0 Hz, 2H), 4.77 (s, 2H), 2.83 (q, J = 8.0 Hz, 2H), 1.21 (t, J = 8.0 Hz, 3H); HRMS (Q-TOF, ESI) calcd for C₁₂H₁₃NO₅ [M + H]⁺ 252.0827, found 252.0896.

4.2.3 Typical procedure for the synthesis of (*tert*-butyl (2-morpholino-2-oxo-1-phenyl ethyl)carbamate) (12a). To the dry DMF solution of 1eq of 2-((*tert*-butoxycarbonyl)amino)-3-phenylpropanoic acid (0.100 g, 0.40 mmol), 2.2eq of EDC (0.17 g, 0.88 mmol) and a catalytic amount of HOBT (0.10 g) were added. The reaction was stirred for 20 minutes under an inert atmosphere, after which the reaction was charged with 3 eq of morpholine (0.104 g, 1.20 mmol). The reaction was then stirred continuously at ambient temperature for 4–5 h under an inert atmosphere. After completion of the reaction as confirmed by TLC, the reaction mixture was poured into crushed ice, filtered, and then dried under vacuum resulting in a solid product (0.11g, 90% yield); ¹H NMR (500 MHz, DMSO-d₆) δ (ppm): 7.25–7.16 (m, 6H), 4.50 (q, J = 10.0 Hz, 1H), 3.73–3.56 (m, 4H), 2.87–2.70 (m, 2H), 2.36 (t, J = 10.0 Hz, 1H), 2.14 (d, J = 15.0 Hz, 1H), 1.27 (s, 9H) HRMS (Q-TOF, ESI) calcd for C₁₈H₂₆N₂O₄ [M + H]⁺ 335.1926, found 335.1893.

4.2.4 Typical procedure for synthesis of 2-amino-1-morpholino-2-phenylethan-1-one (13a). A solution of *tert*-butyl (2-morpholino-2-oxo-1-phenylethyl) carbamate (0.10 g, 0.30 mmol) in 20% TFA in chloroform, was stirred at ambient temperature for 4–5 hours. After completion of the reaction as confirmed by TLC, excess TFA was removed by evaporating with hexane as an azeotropic mixture, yielding 2-amino-1-morpholino-2-phenylethan-1-one (**14a**) in 90% yield. Compound **14a** was used in the subsequent step without any further purification.

4.2.5 Typical procedure for synthesis of (*E*)-*N*-(2-morpholino-2-oxo-1-phenylethyl)-2-(4-(2-nitrobut-1-en-1-yl)phenoxy) acetamide (14a). To the dry DMF solution of 1eq. of (*E*)-2-(4-(2-nitrobut-1-en-1-yl)phenoxy)acetic acid, 11 (0.10 g, 0.40 mmol), 2.2 eq. of EDC (0.17 g, 0.88 mmol) and a catalytic amount of HOBT (0.10 g) were added. The reaction was stirred for 20 minutes under an inert atmosphere, after which the reaction was charged with 3 eq of 2-amino-1-morpholino-2-phenylethan-1-one (0.28 g, 1.20 mmol). The reaction was then stirred continuously at ambient temperature for 4–5 h under an inert atmosphere. After completion of the reaction as confirmed by TLC, the reaction mixture was poured into crushed ice, filtered, and then dried under vacuum resulting in a solid product (1.70 g, 90% yield).

5 Characterization data

5.1 (*E*)-*N*-(1-Morpholino-1-oxo-3-phenylpropan-2-yl)-2-(4-(2-nitrobut-1-en-1-yl) phenoxy)acetamide (14a)

Light yellowish white solid 91% yield; melting point 119.7–120.8 °C; ¹H NMR (400 MHz, CDCl₃) δ 8.00 (s, 1H), 7.42 (d, J = 8.0 Hz, 3H), 7.31 (d, J = 8.0 Hz, 3H), 7.20 (d, J = 8.0 Hz, 2H), 7.01 (d, J = 8.0 Hz, 2H), 5.22 (q, J = 8.0 Hz, 1H), 4.54 (s, 2H), 3.63–3.56 (m, 2H), 3.52–3.40 (m, 3H), 3.32–3.27 (m, 1H), 3.10 (d, J = 8.0 Hz, 1H), 3.06 (d, J = 8.0 Hz, 1H), 3.06–2.97 (m, 1H), 2.96–2.85 (m, 3H), 1.28 (t, J = 8.0 Hz, 3H). ¹³C NMR (100 MHz, CDCl₃)

δ 169.51, 166.99, 158.55, 152.17, 135.79, 132.74, 131.96, 129.67, 128.87, 127.57, 12.28, 115.45, 67.27, 66.52, 66.11, 49.22, 46.14, 42.43, 40.19, 20.91, 12.52; IR (KBr) ν 3392, 3158, 2933, 2744, 1647, 1609, 1563, 1530, 1511, 1462, 1346, 1285, 1247, 1238, 1131, 1054, 976, 875, 769, 623 cm^{−1}; HRMS (Q-TOF, ESI) calcd for C₂₅H₂₉N₃O₆ [M + H]⁺ 468.2056, found 468.2062. Anal. calcd for C₂₅H₂₉N₃O₆: C, 64.23; H, 6.25; N, 8.99. Found: C, 64.29; H, 6.18; N, 9.04.

5.2 (*E*)-1-(2-(Morpholine-4-carbonyl)pyrrolidin-1-yl)-2-(4-(2-nitrobut-1-en-1-yl)phenoxy) ethan-1-one (14b)

Light yellowish white solid 81% yield; melting point 108.4–109.1 °C; ¹H NMR (400 MHz, CDCl₃) δ 7.99 (s, 1H), 7.40 (d, J = 8.0 Hz, 2H), 7.01 (d, J = 8.0 Hz, 2H), 4.91 (dd, J = 4.0, 4.0 Hz, 1H), 4.74 (d, J = 4.0 Hz, 2H), 3.82–3.76 (m, 2H), 3.74–3.60 (m, 6H), 3.57–3.49 (m, 3H), 2.87 (q, J = 8.0 Hz, 2H), 1.27 (t, J = 8.0 Hz, 3H). ¹³C NMR (100 MHz, CDCl₃) δ 170.15, 166.34, 159.66, 151.66, 133.16, 131.98, 129.85, 125.55, 115.41, 115.26, 67.05, 66.92, 56.67, 46.52, 46.28, 42.68, 28.70, 25.70, 20.86, 20.73, 12.47; IR (KBr) ν 3372, 3218, 2927, 2741, 1651, 1609, 1563, 1530, 1511, 1462, 1346, 1285, 1247, 1238, 1131, 1054, 946, 874, 779, 621 cm^{−1}; HRMS (Q-TOF, ESI) calcd for C₂₁H₂₇N₃O₆ [M + H]⁺ 484.1861, found 484.1905. Anal. calcd for C₂₁H₂₇N₃O₆: C, 60.42; H, 6.52; N, 10.07. Found: C, 60.38; H, 6.57; N, 10.11.

5.3 (*E*)-2-(4-(2-Nitrobut-1-en-1-yl)phenoxy)-*N*-(1-oxo-3-phenyl-1-thiomorpholinopropan-2-yl)acetamide (14c)

Light yellowish white solid 74% yield; Melting point 86.8–87.9 °C; ¹H NMR (400 MHz, CDCl₃) δ 8.00 (s, 1H), 7.42 (d, J = 8.0 Hz, 3H), 7.31 (d, J = 8.0 Hz, 3H), 7.18 (d, J = 8.0 Hz, 2H), 7.00 (d, J = 8.0 Hz, 2H), 5.24 (q, J = 8.0 Hz, 1H), 4.52 (s, 2H), 3.83–3.75 (m, 2H), 3.56–3.49 (m, 1H), 3.42–3.37 (m, 1H), 3.04 (d, J = 8.0 Hz, 2H), 2.88 (q, J = 8.0 Hz, 2H), 2.58–2.54 (m, 1H), 2.47–2.38 (m, 2H), 1.90–1.86 (m, 1H), 1.29 (t, J = 8.0 Hz, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 169.56, 166.99, 158.53, 152.18, 135.75, 132.73, 131.96, 129.65, 128.56, 127.55, 126.28, 115.45, 67.24, 49.36, 48.46, 44.97, 40.06, 27.47, 27.34, 20.90, 12.52; IR (KBr) ν 3282, 3148, 2911, 2744, 1647, 1637, 1563, 1530, 1515, 1447, 1346, 1285, 1247, 1238, 1131, 1052, 913, 874, 769, 540 cm^{−1}; HRMS (Q-TOF, ESI) calcd for C₂₅H₂₉N₃O₅S [M + H]⁺ 484.1828, found 484.1837. Anal. calcd for C₂₅H₂₉N₃O₅S: C, 62.09; H, 6.04; N, 8.69; S, 6.63. Found: C, 62.12; H, 5.99; N, 8.73; S, 6.68.

5.4 (*E*)-2-(4-(2-Nitrobut-1-en-1-yl)phenoxy)-1-(2-(thiomorpholine-4-carbonyl)pyrrolidin-1-yl)ethan-1-one (14d)

Light yellow solid 81% yield; melting point 119.1–120.3 °C; ¹H NMR (500 MHz, DMSO) δ 8.06 (s, 1H), 7.56 (d, J = 5.0 Hz, 2H), 7.06 (d, J = 5.0 Hz, 2H), 5.77 (s, 1H), 4.94 (d, J = 15 Hz, 1H), 4.84 (m, 2H), 3.88–3.72 (m, 3H), 3.64–3.57 (m, 3H), 3.47 (d, J = 5.0 Hz, 1H), 2.85 (q, J = 10.0 Hz, 2H), 2.77–2.66 (m, 1H), 2.17–2.13 (m, 1H), 1.98–1.91 (m, 2H), 1.75–1.71 (m, 1H), 1.21 (t, J = 10 Hz, 3H); ¹³C NMR (100 MHz, DMSO): δ 170.19, 165.52, 160.43, 160.37, 151.12, 133.74, 132.51, 124.66, 115.88, 56.87, 55.40, 45.99, 44.88, 31.52, 28.83, 24.88, 22.04, 20.88, 12.49; IR (KBr) ν 3417, 3391, 3157, 3062, 2931, 2742, 2541, 2211. 1929, 1647, 1609, 1563, 1514, 1462, 1346, 1285, 1238, 1131, 1052, 976, 875, 769 cm^{−1}; HRMS (Q-



TOF, ESI) calcd for $C_{21}H_{27}N_3O_5S$ $[M + H]^+$ 434.1671, found 434.1677. Anal. Calcd for $C_{21}H_{27}N_3O_5S$: C, 58.18; H, 6.28; N, 9.69; S, 7.40. Found: C, 58.22; H, 6.26; N, 9.73; S, 7.37.

5.5 (*E*)-*N*-(1-(1*H*-indol-3-yl)-2-morpholino-2-oxoethyl)-2-(4-(2-nitrobut-1-en-1-yl) phenoxy)acetamide (14e)

Light yellow solid 85% yield; melting point 83.1–84.9 °C; 1H NMR (400 MHz, $CDCl_3$) δ 8.14 (s, 1H), 7.99 (s, 1H), 7.66 (d, J = 8.0 Hz, 1H), 7.50 (d, J = 8.0 Hz, 1H), 7.41–7.36 (m, 3H), 7.21 (t, J = 8.0 Hz, 1H), 7.13 (t, J = 8.0 Hz, 1H), 7.07 (s, 1H), 7.00 (d, J = 8.0 Hz, 2H), 5.35 (q, J = 8.0 Hz, 1H), 4.54 (s, 2H), 3.83–3.75 (m, 2H), 3.56–3.49 (m, 1H), 3.42–3.37 (m, 1H), 3.04 (d, J = 8.0 Hz, 2H), 2.88 (q, J = 8.0 Hz, 2H), 2.58–2.54 (m, 1H), 2.47–2.38 (m, 2H), 1.90–1.86 (m, 1H), 1.29 (t, J = 8.0 Hz, 3H). ^{13}C NMR (100 MHz, $CDCl_3$) δ 170.27, 167.05, 158.56, 152.11, 136.18, 132.79, 131.94, 127.54, 126.20, 122.98, 122.67, 120.12, 118.75, 115.46, 111.50, 110.32, 67.29, 48.86, 48.44, 44.86, 30.20, 27.28, 27.21, 20.90, 12.51; IR (KBr) ν 3362, 3178, 2943, 2754, 1637, 1609, 1563, 1516, 1462, 1346, 1284, 1237, 1132, 1054, 975, 871, 769, 591 cm^{-1} ; HRMS (Q-TOF, ESI) calcd for $C_{26}H_{28}N_4O_6$ $[M + H]^+$ 493.2009, found 493.2012. Anal. calcd for $C_{26}H_{28}N_4O_6$: C, 63.40; H, 5.73; N, 11.38. Found: C, 63.45; H, 5.72; N, 11.34.

5.6 (*E*)-2-(4-(2-nitrobut-1-en-1-yl)phenoxy)-*N*-(2-oxo-1-phenyl-2-thiomorpholinoethyl) acetamide (14f)

Light yellow solid 82% yield; melting point 107.0–108.2 °C; 1H NMR (400 MHz, $CDCl_3$) δ 8.10 (d, J = 8.0 Hz, 1H), 7.98 (s, 1H), 7.41–7.29 (m, 7H), 6.98 (d, J = 8.0 Hz, 2H), 5.89 (d, J = 8.0 Hz, 1H), 4.51 (q, J = 8.0 Hz, 2H), 4.19–4.15 (m, 1H), 3.73–3.3.60 (m, 3H), 2.91–2.84 (m, 2H), 2.58 (t, J = 8.0 Hz, 2H), 2.32 (dd, J = 4.0, J = 12.0, Hz, 1H), 1.90–1.86 (m, 1H), 1.42–1.35 (m, 1H). ^{13}C NMR (100 MHz, $CDCl_3$) δ 167.69, 166.67, 158.58, 152.02, 136.92, 132.79, 131.88, 129.45, 128.87, 128.01, 126.09, 115.45, 67.29, 53.86, 48.17, 45.26, 29.79, 27.23, 26.92, 20.86, 12.47; IR (KBr) ν 3312, 3154, 2923, 2735, 1800, 1644, 1603, 1583, 1530, 1511, 1440, 1346, 1285, 1247, 1238, 1179, 1054, 976, 873, 779, 613 cm^{-1} ; HRMS (Q-TOF, ESI) calcd for $C_{24}H_{27}N_3O_5S$ $[M + H]^+$ 470.1671, found 470.1678. Anal. Calcd for $C_{24}H_{27}N_3O_5S$: C, 61.39; H, 5.80; N, 8.95; S, 6.83. found: C, 61.37; H, 5.83; N, 9.01; S, 6.78.

5.7 (*E*)-*N*-(2-morpholino-2-oxo-1-phenylethyl)-2-(4-(2-nitrobut-1-en-1-yl)phenoxy) acetamide (14g)

Light yellow solid 79% yield; melting point 128.5–129.4 °C; 1H NMR (400 MHz, $CDCl_3$) δ 8.08 (d, J = 8.0 Hz, 1H), 7.98 (s, 1H), 7.41–7.31 (m, 7H), 6.98 (d, J = 8.0 Hz, 2H), 5.90 (d, J = 8.0 Hz, 1H), 4.51 (q, J = 8.0 Hz, 2H), 3.78–3.62 (m, 2H), 3.60–3.51 (m, 3H), 3.50–3.42 (m, 1H), 3.29–3.26 (m, 1H), 3.14–3.10 (m, 1H), 2.86 (q, J = 8.0 Hz, 2H), 1.27 (t, J = 4.0 Hz, 3H). ^{13}C NMR (100 MHz, $CDCl_3$) δ 167.81, 166.70, 158.61, 152.06, 136.94, 132.80, 131.90, 129.40, 128.86, 127.95, 126.14, 115.48, 115.16, 67.34, 66.64, 66.07, 53.64, 45.95, 42.86, 20.88, 12.43; IR (KBr) ν 3484.27, 3460.18, 3424.85, 3385.04, 3249.24, 3322.91, 3209.25, 3173.12, 3124.24, 3039.54, 3007.66, 2965.80, 2932.01, 2867.52, 1777.73, 1750.78, 1677.18, 1652.31, 1602.42, 1501.41, 1471.97, 1437.08, 1365.68, 1321.19, 1248.71, 1180.87, 1108.57, 1063.88, 1032.59, 990.68, 945.59, 912.54, 836.85, 811.03, 764.45, 708.25, 662.07, 586.35, 529.62, 484.69, 464.20,

422.40 cm^{-1} ; HRMS (Q-TOF, ESI) calcd for $C_{24}H_{27}N_3O_6$ $[M + H]^+$ 454.1900, found 454.1906. Anal. Calcd for $C_{24}H_{27}N_3O_6$: C, 63.56; H, 6.00; N, 9.27. found: C, 63.53; H, 5.98; N, 9.32.

5.8 Methyl (*E*)-(2-(1*H*-indol-3-yl)-2-(4-(2-nitrobut-1-en-1-yl) phenoxy)acetamido)acetyl)valinate (14h)

Off white solid 89% yield; melting point 128.5–129.4 °C; 1H NMR (400 MHz, $CDCl_3$) δ 8.11 (s, 1H), 7.98 (s, 1H), 7.76 (d, J = 8.0 Hz, 1H), 7.37 (d, J = 8.0 Hz, 4H), 7.21 (t, J = 8.0 Hz, 1H), 7.13 (t, J = 8.0 Hz, 2H), 6.90 (d, J = 8.0 Hz, 2H), 6.11 (d, J = 8.0 Hz, 1H), 4.82 (q, J = 8.0 Hz, 1H), 4.56 (s, 2H), 4.39–4.36 (m, 1H), 3.68 (s, 3H), 3.41–3.36 (m, 1H), 3.22–3.16 (m, 1H), 2.87 (q, J = 8.0 Hz, 2H), 2.05–2.00 (m, 1H), 1.29 (t, J = 4.0 Hz, 3H), 0.79 (d, J = 8.0 Hz, 3H), 0.74 (d, J = 8.0 Hz, 3H). ^{13}C NMR (100 MHz, $CDCl_3$) δ 167.81, 166.70, 158.61, 152.06, 136.94, 132.80, 131.90, 129.40, 128.86, 127.95, 126.14, 115.48, 115.16, 67.34, 66.64, 66.07, 53.64, 45.95, 42.86, 20.88, 12.43; IR (KBr) ν 3322, 3148, 2922, 2742, 1645, 1603, 1563, 1516, 1440, 1346, 1285, 1247, 1238, 1180, 1154, 1034, 946, 809, 701, 530 cm^{-1} ; HRMS (Q-TOF, ESI) calcd for $C_{29}H_{34}N_4O_7$ $[M + H]^+$ 551.2427, found 551.2434. Anal. Calcd for $C_{29}H_{34}N_4O_7$: C, 63.26; H, 6.22; N, 10.18. Found: C, 63.23; H, 6.26; N, 10.15.

5.9 Methyl (*E*)-(2-(4-(2-nitrobut-1-en-1-yl)phenoxy)acetyl) phenylalanylglycinate (14i)

Light yellow white solid 85% yield; melting point 122.5–124.7 °C; 1H NMR (400 MHz, $CDCl_3$) δ 7.99 (s, 1H), 7.40 (d, J = 8.0 Hz, 2H), 7.34 (d, J = 8.0 Hz, 2H), 7.31–7.23 (m, 3H), 7.19 (t, J = 8.0 Hz, 2H), 7.13 (d, J = 8.0 Hz, 1H), 6.94 (d, J = 8.0 Hz, 2H), 4.79 (d, J = 8.0 Hz, 1H), 4.58–4.37 (m, 2H), 4.04–3.89 (m, 2H), 3.73 (s, 2H), 3.16–3.05 (m, 2H), 2.87 (q, J = 8.0 Hz, 2H), 1.28 (t, J = 8 Hz, 3H). ^{13}C NMR (100 MHz, $CDCl_3$) δ 170.95, 169.95, 168.04, 158.43, 152.04, 135.99, 132.63, 131.82, 129.26, 128.63, 127.10, 115.29, 115.25, 67.08, 53.75, 52.40, 41.16, 38.21, 20.74, 12.32. IR (KBr) ν 3475, 3440, 3330, 3170, 3134, 3081, 2924, 2853, 1777, 1750, 1646, 1460, 1402, 1337, 1285, 944, 838, 811, 476 cm^{-1} ; HRMS (Q-TOF, ESI) calcd for $C_{24}H_{27}N_3O_7$ $[M + H]^+$ 470.1849, found 470.1889. Anal. Calcd for $C_{24}H_{27}N_3O_7$: C, 61.40; H, 5.80; N, 8.95. Found: C, 61.41; H, 5.77; N, 8.98.

5.10 Methyl (*E*)-(2-(4-(2-nitrobut-1-en-1-yl)phenoxy)acetyl) tryptophylalaninate (14j)

Light yellow white solid 85% yield; melting point 108.5–109.4 °C; 1H NMR (400 MHz, $CDCl_3$) δ 8.01 (s, 2H), 7.47 (q, J = 4.0 Hz, 2H), 7.42 (d, J = 8.0 Hz, 2H), 7.37 (d, J = 8.0 Hz, 1H), 7.28 (d, J = 4.0 Hz, 2H), 7.23 (d, J = 8.0 Hz, 2H), 6.97 (d, J = 8.0 Hz, 2H), 4.98 (s, 1H), 4.79 (q, J = 8.0 Hz, 1H), 4.54 (s, 1H), 4.45 (q, J = 4.0 Hz, 1H), 3.73 (s, 3H), 3.20–3.08 (m, 2H), 2.12 (q, J = 8.0 Hz, 2H), 1.30 (m, 3H), 0.87 (d, J = 8.0 Hz, 3H). ^{13}C NMR (100 MHz, $CDCl_3$) δ 171.64, 170.28, 167.72, 158.36, 152.13, 135.95, 132.53, 131.84, 131.01, 129.29, 128.78, 127.21, 126.23, 121.94, 116.22, 115.27, 67.17, 57.51, 54.17, 38.18, 31.11, 20.77, 12.39. IR (KBr) ν 3397, 3293, 3220, 3199, 3174, 2975, 2924, 2853, 1779, 1742, 1649, 1602, 1401, 1364, 1177, 1059, 1025, 944, 837, 811, 742, 699, 475, 423 cm^{-1} ; HRMS (Q-TOF, ESI) calcd for $C_{27}H_{30}N_4O_7$ $[M + H]^+$



523.2114, found 523.2148. Anal. Calcd for $C_{27}H_{30}N_4O_7$: C, 62.06; H, 5.79; N, 10.72. found: C, 62.10; H, 5.82; N, 10.68.

5.11 Methyl (E)-(2-(4-(2-nitrobut-1-en-1-yl)phenoxy)acetyl)phenylalanylalaninate (14k)

Light yellow white solid 85% yield; melting point 118.2–120.4 °C; 1H NMR (400 MHz, $CDCl_3$) δ 8.35 (s, 1H), 7.99 (s, 2H), 7.69 (d, J = 8 Hz, 1H), 7.55 (d, J = 4 Hz, 1H), 7.20 (t, J = 8 Hz, 1H), 7.12 (d, J = 12 Hz, 2H), 7.00 (d, J = 8.0 Hz, 2H), 6.89 (d, J = 8.0 Hz, 2H), 4.85 (q, J = 8.0 Hz, 1H), 4.70 (s, 2H), 4.46 (t, J = 8 Hz, 1H), 3.69 (s, 2H), 3.38 (m, 1H), 3.24 (m, 1H), 2.88 (q, J = 8 Hz, 2H), 1.34–1.24 (m, 6H). ^{13}C NMR (100 MHz, $CDCl_3$) δ 172.77, 170.69, 168.15, 159.12, 151.82, 136.28, 133.49, 132.80, 131.79, 123.59, 122.32, 119.88, 118.63, 116.25, 115.18, 111.37, 77.39, 77.07, 76.75, 67.04, 52.55, 48.42, 28.34, 20.77, 18.05, 12.31. IR (KBr) ν 3328, 3277, 3249, 3198, 2979, 2441, 1776, 1744, 1651, 1602, 1510, 1457, 1402, 1365, 1181, 1063, 1026, 945, 837, 810, 739, 505, 470, 423 cm^{-1} ; HRMS (Q-TOF, ESI) calcd for $C_{25}H_{29}N_3O_7$ $[M + H]^+$ 483.2006, found 483.2039. Anal. Calcd for $C_{25}H_{29}N_3O_7$: C, 62.10; H, 6.05; N, 8.69. found: C, 62.08; H, 6.01; N, 8.63.

5.12 Pharmacology

5.12.1 Leishmania parasite culture and maintenance. The parasite used was *Leishmania donovani*, strain (MHOM/SD/62/1S (Ahuja *et al.* 2015)). The promastigote stage of the parasite was regularly grown at 26 °C in medium M199 with 10% heat-inactivated fetal bovine serum (FBS), streptomycin (100 μg mL^{-1}), and penicillin 100 (IU mL^{-1}). The promastigotes in log phase were sub-cultured after every 72 hours using a 2×10^6 cells per mL inoculum (Ahuja *et al.* 2015).

5.13 Cell line culture

THP-1 human macrophages were cultured in RPMI based medium at 37 °C in presence of 5% CO_2 for 48 to 72 hours in RPMI-1640 medium (pH 7.4) with 10% heat-inactivated FBS in a 5% CO_2 humidified atmosphere (Avishek *et al.* 2024). Afterwards, an average density of 2×10^5 cells per mL of the cells were transferred to new RPMI-1640 medium.

5.14 MTT assay for anti-promastigote activity

The anti-leishmanial activity of peptidyl β -nitrostyrenes (14a–k) was performed using MTT assay (Sharma *et al.* 2023). This assay is based on the mitochondrial enzymes NAD and NADH-dehydrogenases forming formazan crystals from the tetrazolium soluble salt. 10 000 THP-1 human monocytic cells were seeded at per well in a 96-well plate. The cells were exposed to the synthesized molecules at varying concentrations starting from 100, 50, 25, 12.5, and 6.25 μM , for 24 hours after they reached normal morphology. The 96-well plate was then kept in an incubator with humidified CO_2 at 37 °C. Following this, the supernatant was discarded, followed by addition of 0.5 mg mL^{-1} of MTT solution. It was then incubated for 4 hours at 37 °C in a humidified environment. The media was taken out, followed by the addition of DMSO to dissolve the formazan crystals, and an i3x spectramax molecular device was used to record the

absorbance at 570 nm. Compounds showing greater than 50% inhibition were selected for cytotoxicity assay (IC_{50}).³¹

5.15 Anti-leishmanial activity against *L. donovani* promastigotes

The synthesized molecules were tested for their *in vitro* activity against *L. donovani* promastigotes. A concentration of 2×10^6 cells per mL of *L. donovani* promastigotes were cultured in RPMI medium for 72 hours at 26 °C with 100 μM concentration of each compound. Amphoterecin B (AmphoB) was used as a reference, and DMSO (0.2%) was the solvent. Parasites in media alone were the control experiment. The viability of parasites was measured using the MTT assay after 72 hours.³²

5.16 Determination of IC_{50} from dose-dependent anti-promastigote activity

The promastigotes of *L. donovani* were incubated using 2×10^6 cells per mL in the presence and absence of the most active compounds (14a–i) of the series at serial dilutions starting at 25 μM for 72 hours at 26 °C, using AmphoB as a standard anti-leishmanial drug control. Cell viability was measured using by MTT assay, and the following formula was used to calculate the mean percentage viability: (Mean cell number of treated promastigotes/Mean cell number of untreated promastigotes) $\times 100$. The IC_{50} values were determined by extrapolation of graph in the graph of % viability vs. concentration of the drug.³³

5.17 Cytotoxicity assay

THP-1 human monocytic cells were cultured with 10% FBS in RPMI media, and 1×10^6 cells per mL concentration of cells were seeded. The plate was kept in a humidified CO_2 incubator for 24 h at 37 °C. After 24 h, media was removed, and varying concentrations of standard and compounds were added like 100, 50, 25, 12.5, and 6.25 μM for 72 h, before performing the MTT assay.³⁴

5.18 Intracellular amastigotes assay

Macrophages of *L. donovani* were cultivated on eight-chamber tissue culture slides with 5×10^4 cells in each well and were allowed to adhere in a CO_2 incubator containing 5% CO_2 for 2 h at 37 °C. RPMI 1640 medium without serum was used to wash the wells twice to eliminate the nonadherent macrophages. The adherent macrophages were subsequently exposed to the metacyclic stage of *Leishmania donovani*, with a *Leishmania* to macrophage ratio of 10 : 1, which was sustained overnight in a 200 μL final solution of complete RPMI 1640 medium. Following a 24 hours incubation period, RPMI 1640 medium with no serum was used to wash free promastigotes. Infected macrophages were then incubated with compounds in duplicate for 72 hours at 37 °C with 5% CO_2 , except the control well. The number of amastigotes in 100 macrophages were counted at each concentration to evaluate IC_{50} values of test compounds. Infected macrophage percentages were determined by counting the infected macrophages per 100 macrophages.³⁵



5.19 Calculation of percentage of inhibition and ED₅₀

Using a Neubauer chamber, the extracellular parasites present in treated wells as well as control wells were counted after 24 hours of treatment. For every duplicate well, a microscopic enumeration was conducted at various concentrations. Dead parasites with deteriorated body surfaces were not counted. All counts at varying concentrations were converted to percentages by using the control well mean, which was taken to represent 100% survival. Using Zeiss, AXIO, and Imager A1 light microscope, the slides of the infected macrophage cell line which were stained with Giemsa, were examined, and the infected macrophages/amastigotes per 100 cells were counted.³⁶

5.20 Statistical analysis

IC₅₀ values against *L. donovani* promastigotes and amastigotes were determined from the triplicate's experiments for the mean and standard error of the mean (SEM). To analyze the differences among groups GraphPad Prism 8.0 software was used. Using the two-way ANOVA, the correlation between drug and their effect was determined. $P < 0.05$ was regarded as being statistically important for difference and correlation.³⁷

5.21 In Vitro cysteine protease inhibition assay

Inhibition of papain (Roche cat #10108014001) was studied using an increasing concentration of the derivatives. N α -Benzoyl-L-arginine-7-amido-4-methyl coumarin hydrochloride (Bz-Arg-AMC) from Sigma (cat #B7260), a fluorogenic peptide substrate was used for the papain activity assay. The inhibitors were dissolved in DMSO and an activation buffer containing sodium acetate buffer (pH 5.5), 8 mM DTT, and 4 mM EDTA was used. The reaction mixture (100 μ l) also included papain (4 mM), increasing concentration of inhibitor (0–32 μ M) and 10 μ M substrate. The enzymatic hydrolysis of substrate by papain was monitored using SpectraMax Multi-Mode Microplate Readers with an emission wavelength of 440 nm and an excitation wavelength of 345 nm. The IC₅₀ value for the inhibitor was calculated from the plot of the % residual activity against the log[inhibitor], as described previously.³⁸

5.22 Molecular docking

5.22.1 Protein preparation. The protein structure of cysteine proteases (PDB ID: 6P4E) with a resolution of 1.16 Å was obtained from the Protein Data Bank (PDB) (RCSB). The best resolution values, *R*-free and *R*-work, are 0.130 and 0.110, respectively, and the number of resolved residues was considered. The ligand was initially analyzed by Schrödinger's protein preparation wizard panel (Schrödinger). Without undergoing any additional modification to the protein in monomeric form, the ligand was retained and crystallized water molecules were removed. When preparing proteins, the OPLS3 2015 force field was utilised to minimise the amount of protein energy. Following protein preparation, the receptor grid generation tool was employed and a grid surrounding the ligand was

created while utilising all of the Glide tool's standard parameters.^{39,40}

5.22.2 Ligand preparation. All the synthesized compounds were drawn in the workspace in Maestro 2D along with the standard. Ligand preparation was initiated after entering all entities. The prepared ligands and receptor grid were docked using the standard procedure of Glide XP docking. The docking scores and poses are presented after the completion of the process.

5.22.3 Ligand docking. For molecular docking or Glide XP docking, the protein was prepared, the grid was generated, and the ligands were prepared. The standard protocol of Glide (Schrödinger's) was employed with a partial charge cut-off of 0.15 and a scaling factor of 0.8 for nonpolar atom's van der Waal radii were employed. Each ligand produced ten poses, and residues within 5 Å of the grid center had per-residue interaction scores calculated.

5.22.4 ADMET analysis. All final compounds were subjected to ADMET analysis using QikProp module of maestro. It provides ranges for comparing the properties of a particular molecule with those of 95% of known drugs. The descriptors calculated were partition coefficient, human oral absorption, Lipinski rule of five *etc.*

5.22.5 MD simulations. Molecular dynamics simulation is a computational technique employed to investigate the dynamic behavior of molecular systems complex of protein and ligand over time. It provides an analysis of the physical movements of atoms and molecules. The atoms and molecules are allowed to interact for a fixed period, giving a view of the dynamic evolution of the system (protein–ligand complex) at the atomic or molecular level. The top-scoring protein–ligand complexes (Glide docked), with high binding free energies (ΔG Bind), were submitted to a 100 ns MD simulation using the GROMACS suite 2024.4, a widely used MD simulation package to obtain root mean square deviation (RMSD), root mean square fluctuation (RMSF), radius of gyration (Rg), hydrogen bonds, and SASA for the evaluation of dynamic behavior and stability of the protein–ligand complexes. The topology of the protein was generated by GROMACS 2024.4 using the CHARMM27 force field, and the topology and parameters of the ligands were generated from the website SwissParam (<https://swissparam.ch/>). The systems were solvated using the TIP3P water model and the ions were added to neutralize the system and to achieve the desired ionic strength, using Na⁺, Cl[−] at the concentration 0.10 M NaCl. The prepared system was further subjected to energy minimization to remove any steric clashes and ensure a stable starting configuration. Additionally, an index file was generated, and the.mdp file was modified to define the thermal coupling group and adjust position restraints. Minimized systems subjected to equilibration phases (NVT and NPT), including heating to the desired temperature (300 K) and pressure (1.01325 bar), were used to stabilize the system for the final production MD simulations run. Long-range MD simulations were conducted under periodic boundary conditions. The post-MD simulation trajectories were analysed and visualized using the different tools of GROMACS, and VMD, and data plots were generated using Grace.



Data availability

The data supporting this article have been included as part of the ESI.†

Conflicts of interest

The authors declare no conflict of interest.

Acknowledgements

We would like to show our gratitude to SERB (ECR/2017/001067/CS) for financial support and Jamia Hamdard for providing the laboratory facilities.

References

- 1 E. Torres-Guerrero, M. Romano Quintanilla-Cedillo, J. Ruiz-Esmenjaud, R. Arenas, F. Bravo-Puccio, P. Cayetano Heredia and R. J. Hay, *F1000Research*, 2017, **6**, 750.
- 2 P. Desjeux, *Comp. Immunol., Microbiol. Infect. Dis.*, 2004, **27**, 305–318.
- 3 A. Selvapandian, S. L. Croft, S. Rijal, H. L. Nakhasi and N. K. Ganguly, *PLoS Neglected Trop. Dis.*, 2019, **13**, e0007616.
- 4 P. Bhattacharya, R. Dey, P. K. Dagur, A. B. Joshi, N. Ismail, S. Gannavaram, A. Debrabant, A. D. Akue, M. A. KuKuruga, A. Selvapandian, J. P. McCoy and H. L. Nakhasi, *PLoS Neglected Trop. Dis.*, 2016, **10**, e0004963.
- 5 M. M. S. Andrade, L. C. Martins, G. V. L. Marques, C. A. Silva, G. Faria, S. Caldas, J. S. C. Dos Santos, V. G. Maltarollo, R. S. Ferreira and R. B. Oliveira, *Future Med. Chem.*, 2020, **12**, 571–581.
- 6 A. Latorre, T. Schirmeister, J. Kesselring, S. Jung, P. Johé, U. A. Hellmich, A. Heilos, B. Engels, R. L. Krauth-Siegel, N. Dirdjaja, L. Bou-Iserte, S. Rodríguez and F. V. González, *ACS Med. Chem. Lett.*, 2016, **7**, 1073–1076.
- 7 S. Sharma, P. A. Yakkala, J. Aboti, I. Latief, M. A. Ansari, W. H. Khan and S. Shafi, *ChemistrySelect*, 2023, **8**, e202300912.
- 8 P. J. Rosenthal, G. K. Lee and R. E. Smith, *J. Clin. Invest.*, 1993, **91**, 1052–1056.
- 9 J. H. McKerrow, *Int. J. Parasitol.*, 1999, **29**, 833–837.
- 10 H. Mahmoudzadeh-Niknam and J. H. McKerrow, *Exp. Parasitol.*, 2004, **106**, 158–163.
- 11 S. T. Liang, C. Chen, R. X. Chen, R. Li, W. L. Chen, G. H. Jiang and L. L. Du, *Front. Pharmacol.*, 2022, **13**, 1033003.
- 12 S. Sharma, P. Anjaneyulu Yakkala, M. A. Beg, S. Tanwar, I. Latief, A. Khan, K. Sharma, S. ur Rehman, A. Selvapandian and S. Shafi, *ChemistrySelect*, 2023, **8**, e202302415.
- 13 Evaluation of nitrostyrenes as antifungal agents. I. *In vitro* studies - PubMed, <https://pubmed.ncbi.nlm.nih.gov/24544016/>, (accessed 24 March 2024).
- 14 Antifungal activity of beta-nitrostyrenes and some cyclohexane derivatives - PubMed, <https://pubmed.ncbi.nlm.nih.gov/24543964/>, (accessed 24 March 2024).
- 15 A. Ramzan, S. A. Padder, K. Z. Masoodi, S. Shafi, I. Tahir, R. U. Rehman, R. Prasad and A. H. Shah, *Eur. J. Med. Chem.*, 2022, **240**, 114609.
- 16 Y. Mikami, K. Yazawa, A. Maeda, J. Uno, A. Kubo, N. Saito and N. Kawakami, *J. Antibiot.*, 1991, **44**, 1454–1456.
- 17 N. Milhazes, R. Calheiros, M. P. M. Marques, J. Garrido, M. N. D. S. Cordeiro, C. Rodrigues, S. Quinteira, C. Novais, L. Peixe and F. Borges, *Bioorg. Med. Chem.*, 2006, **14**, 4078–4088.
- 18 S. Shafi, F. Afrin, M. Islamuddin, G. Chouhan, I. Ali, F. Naaz, K. Sharma and M. S. Zaman, *Front. Microbiol.*, 2016, **7**, 195169.
- 19 Z. Jun Jia, X. Wei Lan, K. Lu, X. Meng, W. Jie Jing, S. Ru Jia, K. Zhao and Y. Jie Dai, *J. Mol. Struct.*, 2023, **1284**, 135409.
- 20 C. Schad, U. Baum, B. Frank, U. Dietzel, F. Mattern, C. Gomes, A. Ponte-Sucre, H. Moll, U. Schurig and T. Schirmeister, *Antimicrob. Agents Chemother.*, 2015, **60**, 797–805.
- 21 A. Scala, N. Micale, A. Piperno, A. Rescifina, T. Schirmeister, J. Kesselring and G. Grassi, *RSC Adv.*, 2016, **6**, 30628–30635.
- 22 A. Latorre, T. Schirmeister, J. Kesselring, S. Jung, P. Johé, U. A. Hellmich, A. Heilos, B. Engels, R. L. Krauth-Siegel, N. Dirdjaja, L. Bou-Iserte, S. Rodríguez and F. V. González, *ACS Med. Chem. Lett.*, 2016, **7**, 1073–1076.
- 23 Y. Zhou, P. Vedantham, K. Lu, J. Agudelo, R. Carrion, J. W. Nunneley, D. Barnard, S. Pöhlmann, J. H. McKerrow, A. R. Renslo and G. Simmons, *Antiviral Res.*, 2015, **116**, 76–84.
- 24 J. J. Shie, J. M. Fang, T. H. Kuo, C. J. Kuo, P. H. Liang, H. J. Huang, Y. T. Wu, J. T. Jan, Y. S. E. Cheng and C. H. Wong, *Bioorg. Med. Chem.*, 2005, **13**, 5240–5252.
- 25 A. Citarella, A. Scala, A. Piperno and N. Micale, *Biomolecules*, 2021, **11**, 607.
- 26 K. Akaji, H. Konno, H. Mitsui, K. Teruya, Y. Shimamoto, Y. Hattori, T. Ozaki, M. Kusunoki and A. Sanjoh, *J. Med. Chem.*, 2011, **54**, 7962–7973.
- 27 S. Previti, R. Ettari, E. Calcaterra, S. Di Maro, S. J. Hammerschmidt, C. Müller, J. Ziebuhr, T. Schirmeister, S. Cosconati and M. Zappalà, *Eur. J. Med. Chem.*, 2023, **247**, 115021.
- 28 T. P. C. Dorlo, M. Balasegaram, J. H. Beijnen and P. J. de Vries, *J. Antimicrob. Chemother.*, 2012, **67**, 2576–2597.
- 29 The treatment of visceral leishmaniasis: safety and efficacy - PubMed, <https://pubmed.ncbi.nlm.nih.gov/25327244/>, (accessed 17 October 2024).
- 30 J. D. Herman, *Rev. Infect. Dis.*, 1988, **10**, 560–586.
- 31 P. A. Yakkala, S. R. Panda, S. Shafi, V. G. M. Naidu, M. S. Yar, P. N. Ubanako, S. A. Adeyemi, P. Kumar, Y. E. Choonara, E. v. Radchenko, V. A. Palyulin and A. Kamal, *Molecules*, 2022, **27**, 7642.
- 32 O. Gupta, T. Pradhan, R. Bhatia and V. Monga, *Eur. J. Med. Chem.*, 2021, **223**, 113606.
- 33 G. Chouhan, M. Islamuddin, M. Y. Want, M. Z. Abidin, H. A. Ozbak, H. A. Hemeg, D. Sahal and F. Afrin, *Parasites Vectors*, 2015, **8**, 183.
- 34 R. N. Duffin, V. L. Blair, L. Kedzierski and P. C. Andrews, *J. Inorg. Biochem.*, 2020, **203**, 110932.
- 35 K. Vats, R. Tandon, Roshanara, M. A. Beg, R. M. Corrales, A. Yagoubat, E. Reyaz, T. H. Wani, M. S. Baig,



- A. Chaudhury, A. Krishnan, N. Puri, P. Salotra, Y. Sterkers and A. Selvapandiyan, *Biochim. Biophys. Acta, Mol. Cell Res.*, 2023, **1870**, 119416.
- 36 K. Das Manandhar, T. P. Yadav, V. K. Prajapati, S. Kumar, M. Rai, A. Dube, O. N. Srivastava and S. Sundar, *J. Antimicrob. Chemother.*, 2008, **62**, 376–380.
- 37 V. V. Andrade-Neto, K. M. Rebello, T. M. Pereira and E. C. Torres-Santos, *Antimicrob. Agents Chemother.*, 2021, **65**, 1–11.
- 38 E. Pitsillou, J. Liang, K. Ververis, A. Hung and T. C. Karagiannis, *J. Mol. Graphics Modell.*, 2021, **104**, 107851.
- 39 H. Krishna, P. Anchi, K. Lakshmi, J. Prakash, C. Godugu, N. Shankaraiah and A. Kamal, *Bioorg. Chem.*, 2021, **117**, 105461.
- 40 P. A. Yakkala, S. R. Panda, S. Shafi, V. G. M. Naidu, M. S. Yar, P. N. Ubanako, S. A. Adeyemi, P. Kumar, Y. E. Choonara, E. V. Radchenko, V. A. Palyulin and A. Kamal, *Molecules*, 2022, **27**, 7642.

